|
|
Volumn 29, Issue 36, 2011, Pages 4545-
|
|
Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
LAPATINIB;
PAZOPANIB;
ANGIOGENESIS INHIBITOR;
ANTINEOPLASTIC AGENT;
PYRIMIDINE DERIVATIVE;
QUINAZOLINE DERIVATIVE;
SULFONAMIDE;
ADVANCED CANCER;
CANCER CHEMOTHERAPY;
CANCER SURVIVAL;
HUMAN;
LETTER;
MONOTHERAPY;
OPEN STUDY;
OVERALL SURVIVAL;
PHASE 2 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
RECURRENT CANCER;
TREATMENT RESPONSE;
UTERINE CERVIX CANCER;
FEMALE;
NOTE;
UTERINE CERVIX TUMOR;
ANGIOGENESIS INHIBITORS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
FEMALE;
HUMANS;
PYRIMIDINES;
QUINAZOLINES;
SULFONAMIDES;
UTERINE CERVICAL NEOPLASMS;
|
|
EID: 84555197179
PISSN: 0732183X
EISSN: 15277755
Source Type: Journal
DOI: 10.1200/JCO.2011.38.8777 Document Type: Letter |
|
Times cited : (41)
|
|
References (1)
|
